Cardiac fibrosis is mediated by the activation of resident cardiac fibroblasts, which
differentiate into myofibroblasts in response to injury or stress. Although myofibroblast …

Pulmonary fibrosis (PF) is a progressive, and life-threatening interstitial lung disease which
causes scarring in the lung parenchyma and thereby affects architecture and functioning of …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disorder of unknown origin and
the most common interstitial lung disease. It progresses with the recruitment of fibroblasts …

Fibrosis is the final pathological outcome and major cause of morbidity and mortality in many
common and chronic inflammatory, immune-mediated, and metabolic diseases. Despite the …

CTGF is upregulated in patients with idiopathic pulmonary fibrosis (IPF), characterized by
the deposition of a pathological extracellular matrix (ECM). Additionally, many omics studies …

Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that
affects alveoli elasticity, which leading to higher rates of hospitalization and mortality …

Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease characterized by
myofibroblast accumulation and progressive lung scarring. To identify transcriptional gene …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized
by excessive deposition of fibrotic connective tissue in the lungs. Emerging evidence …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown cause that is characterized
by progressive fibrotic lung remodeling. An abnormal emergence of airway epithelial‐like …

Drug-induced lung injury leading to pulmonary fibrosis is an interstitial lung pathology
destructing the architecture of lung. Although animal models have been used to understand …